Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Using decision tree learning to predict the responsiveness of hepatitis C patients to drug treatment.

Kawamura Y, Takasaki S, Mizokami M.

FEBS Open Bio. 2012 May 11;2:98-102. doi: 10.1016/j.fob.2012.04.007. Print 2012.

2.

Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.

Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, Sugiyama M, Matsuura K, Sugauchi F, Asahina Y, Nakagawa M, Watanabe M, Sakamoto M, Maekawa S, Sakai A, Kaneko S, Ito K, Masaki N, Tokunaga K, Izumi N, Mizokami M.

J Hepatol. 2011 Mar;54(3):439-48. doi: 10.1016/j.jhep.2010.07.037. Epub 2010 Sep 19.

PMID:
21129805
3.

Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.

Lok AS, Gardiner DF, Hézode C, Lawitz EJ, Bourlière M, Everson GT, Marcellin P, Rodriguez-Torres M, Pol S, Serfaty L, Eley T, Huang SP, Li J, Wind-Rotolo M, Yu F, McPhee F, Grasela DM, Pasquinelli C.

J Hepatol. 2014 Mar;60(3):490-9. doi: 10.1016/j.jhep.2013.10.019. Epub 2013 Oct 26.

PMID:
24444658
4.

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.

Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M.

Nat Genet. 2009 Oct;41(10):1105-9. doi: 10.1038/ng.449. Epub 2009 Sep 13.

PMID:
19749757
5.

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?

Gonçales FL Jr, Moma CA, Vigani AG, Angerami AF, Gonçales ES, Tozzo R, Pavan MH, Gonçales NS.

BMC Infect Dis. 2010 Jul 20;10:212. doi: 10.1186/1471-2334-10-212.

7.

Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype.

Guo X, Zhao Z, Xie J, Cai Q, Zhang X, Peng L, Gao Z.

Virol J. 2012 Jun 19;9:123. doi: 10.1186/1743-422X-9-123.

8.

Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin.

Laguno M, Larrousse M, Murillas J, Blanco JL, León A, Milinkovic A, Loncá M, Martinez E, Sánchez-Tapias JM, de Lazzari E, Gatell JM, Costa J, Mallolas J.

J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):174-8.

PMID:
17106276
9.

Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin.

McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, Tillmann HL, Muir AJ, McHutchison JG.

Gastroenterology. 2010 Jun;138(7):2307-14. doi: 10.1053/j.gastro.2010.02.009. Epub 2010 Feb 19.

10.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

11.

Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin.

Oze T, Hiramatsu N, Yakushijin T, Kurokawa M, Igura T, Mochizuki K, Imanaka K, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Hijioka T, Tamura S, Yoshihara H, Hayashi E, Inoue A, Imai Y, Kato M, Yoshida Y, Tatsumi T, Ohkawa K, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N.

J Viral Hepat. 2009 Aug;16(8):578-85. doi: 10.1111/j.1365-2893.2009.01116.x. Epub 2009 Jun 22.

PMID:
19552663
12.

Interleukin-10.rs1800896 and Interleukin-18.rs1946518 gene polymorphisms could not predict the outcome of hepatitis C virus infection in Egyptian patients treated with pegylated interferon plus ribavirin.

Abdelraheem WM, Hassuna NA, Abuloyoun SM, Abdel Ghany HM, Rizk HA, Abdelwahab SF.

Arch Virol. 2016 Sep;161(9):2473-80. doi: 10.1007/s00705-016-2948-y. Epub 2016 Jun 28.

PMID:
27352267
13.

[Differential response to pegylated interferon plus ribavirin combination therapy in chronic hepatitis C and HIV/HCV co-infected patients].

Liu B, Cai WP, Hu FY, Xu M, Lan Y, Tang XP.

Zhonghua Gan Zang Bing Za Zhi. 2013 Nov;21(11):829-33. doi: 10.3760/cma.j.issn.1007-3418.2013.11.008. Chinese.

PMID:
24331692
14.

FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients.

Pineda-Tenor D, Berenguer J, Jiménez-Sousa MA, García-Alvarez M, Aldámiz-Echevarria T, Carrero A, Vázquez-Morón S, García-Broncano P, Diez C, Tejerina F, Guzmán-Fulgencio M, Resino S.

BMC Med. 2014 Nov 3;12:198. doi: 10.1186/s12916-014-0198-y.

15.

Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b.

Yoshizawa K, Abe H, Aida Y, Ishiguro H, Ika M, Shimada N, Tsubota A, Aizawa Y.

J Med Virol. 2013 Jul;85(7):1180-90. doi: 10.1002/jmv.23597.

PMID:
23918536
16.

Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.

Jabłonowska E, Piekarska A, Koślińska-Berkan E, Omulecka A, Szymańska B, Wójcik K.

Acta Biochim Pol. 2012;59(3):333-7. Epub 2012 Aug 27.

17.

Serum lipoprotein profiles and response to pegylated interferon plus ribavirin combination therapy in patients with chronic HCV genotype 1b infection.

Aizawa Y, Shimada N, Abe H, Seki N, Aida Y, Ishiguro H, Ika M, Kato K, Tsubota A.

Hepat Mon. 2013 May 27;13(5):e8988. doi: 10.5812/hepatmon.8988. eCollection 2013 May.

18.

Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4.

Domagalski K, Pawłowska M, Tretyn A, Halota W, Pilarczyk M, Smukalska E, Linkowska K, Grzybowski T.

Eur J Clin Microbiol Infect Dis. 2013 Jun;32(6):745-54. doi: 10.1007/s10096-012-1799-z. Epub 2013 Jan 13.

19.

IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection.

Eslam M, Leung R, Romero-Gomez M, Mangia A, Irving WL, Sheridan D, Spengler U, Mollison L, Cheng W, Bugianesi E, McLeod D, Zaitoun AM, Attino V, Goeltz D, Nattermann J, Douglas M, Booth DR, George J, Ahlenstiel G.

J Hepatol. 2014 Aug;61(2):235-41. doi: 10.1016/j.jhep.2014.03.039. Epub 2014 Apr 24.

PMID:
24768758
20.

Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.

Kim SR, El-Shamy A, Imoto S, Kim KI, Ide YH, Deng L, Shoji I, Tanaka Y, Hasegawa Y, Ota M, Hotta H.

J Gastroenterol. 2012 Oct;47(10):1143-51. doi: 10.1007/s00535-012-0578-z. Epub 2012 Mar 24.

PMID:
22441534

Supplemental Content

Support Center